• bioAffinity Technologies advanced a new clinical use for its CyPath Lung test to monitor lung cancer survivors for recurrence or new cancers.
• No new study results were presented; the update focused on expanding surveillance use based on prior trials and commercial experience.
• The test aims to complement CT scans by helping clinicians judge whether new or changing lung nodules are more likely malignant.
• The move targets a large follow-up market, with more than 680,000 Americans living with a prior lung cancer diagnosis as of Jan. 1, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. bioAffinity Technologies Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202609010800BIZWIRE_USPR_____20260901_BW798354) on September 01, 2026, and is solely responsible for the information contained therein.